BRIEF-Merck, Pfizer say investigational Ertugliflozin met primary endpoint
 

BRIEF-Merck, Pfizer say investigational Ertugliflozin met primary endpoint
* Merck and pfizer an**unce investigational Ertugliflozinmet primary endpoint of A1C reduction when added to Sitagliptinand Metformin in people with type 2 diabeteshttp://feeds.feedburner.com/~ff/reut...?d=yIl2AUoC8zA http://feeds.feedburner.com/~ff/reut...u8:V_sGLiPBpWU http://feeds.feedburner.com/~ff/reut...u8:F7zBnMyn0Lo
http://feeds.feedburner.com/~r/reute...~4/AjC3uvetcz0